FRACTYL HEALTH, INC.: Results of Operations and Financial Condition (GUTS)

Nov 12, 2026, 4:14 PM ETResultsRead the original at SEC EDGAR

Good for GUTS

Fractyl's Revita study showed patients kept about 80% of GLP-1-related weight loss, versus 67% with sham, supporting its planned FDA filing. Staff cuts and stopping Rejuva narrow its plans, but lower spending leaves cash into Q2 2027.

GUTS · Fractyl Health, Inc.

AI read · Good for GUTS

The AI's read

The study result gives Fractyl stronger support for its planned FDA filing and makes Revita its main focus. Cutting about 45% of staff and stopping Rejuva work shrink its plans, but also lower spending. The company says its cash lasts into Q2 2027, through the filing and expected 12-month results.

Get alerts for GUTS

Follow Fractyl Health, Inc. (GUTS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GUTS

Free on the App Store and Google Play, or on the web.